Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Grow up and move on please...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Nov 15, 2022 12:25pm
159 Views
Post# 35100319

RE:Grow up and move on please...

RE:Grow up and move on please...Read the financials. Either a deal is imminent or this company gets sold. Real soon on either option. Stop your nonsense please.

As I've posted before, if the company will be sold I would prefer an outright sell if possible -- $2 US per share would be fine, I'll hold my nose and vote yes for $1 US.

I'd be opposed to a Contingency Value Rights (CVR) deal.  Some small amount of cash up front and potentially, possibly, maybe more IF certain milestones are met down the road, IF completed by certain dates. Years more waiting and any visibility into how the process is moving forward is gone.

The Forbes article I've posted before outlines some of the downside features of CVR deals.  All the risk is "on the backs of investors in their target corporation".

IMO, with a CVR deal, many pharmas' first priority is to do everything possible to minimize or avoid any future payout to shareholders. This article discusses two court cases re CVR deals where shareholders alleged the pharmas avoided payments by taking an inordinate amount of time moving forward.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities